<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xencor Inc — News on 6ix</title>
<link>https://6ix.com/company/xencor-inc</link>
<description>Latest news and press releases for Xencor Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 04 Mar 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/xencor-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835dca478dffbe2df124624.webp</url>
<title>Xencor Inc</title>
<link>https://6ix.com/company/xencor-inc</link>
</image>
<item>
<title>Xencor Announces Change to Ultomiris® Royalty Revenue Forecast</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-announces-change-to-ultomirisr-royalty-revenue-forecast-103</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-announces-change-to-ultomirisr-royalty-revenue-forecast-103</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track</description>
</item>
<item>
<title>Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-highlights-corporate-priorities-2026-130100384</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-highlights-corporate-priorities-2026-130100384</guid>
<pubDate>Thu, 08 Jan 2026 13:01:00 GMT</pubDate>
<description>PASADENA, Calif., January 08, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates.</description>
</item>
<item>
<title>Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-announces-extension-us-patent-term-certain-xtendtm-antibodies-2025-12-09</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-announces-extension-us-patent-term-certain-xtendtm-antibodies-2025-12-09</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years -- -- Additional $100</description>
</item>
<item>
<title>Xencor to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-participate-upcoming-investor-conferences-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-participate-upcoming-investor-conferences-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-reports-third-quarter-2025-financial-results-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-reports-third-quarter-2025-financial-results-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-presents-initial-data-xmab819-first-class-enpp3-x-cd3-bispecific-t-cell</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-presents-initial-data-xmab819-first-class-enpp3-x-cd3-bispecific-t-cell</guid>
<pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
<description>-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range</description>
</item>
<item>
<title>Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-host-webcast-and-conference-call-discuss-initial-results-ongoing-phase-1-dose</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-host-webcast-and-conference-call-discuss-initial-results-ongoing-phase-1-dose</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-announces-presentation-initial-phase-1-dose-escalation-results-xmab819-clear</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-announces-presentation-initial-phase-1-dose-escalation-results-xmab819-clear</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>-- Management to host webcast and conference call on Friday, October 24, 2025 -- PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a</description>
</item>
<item>
<title>Xencor Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-reports-second-quarter-2025-200100532</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-reports-second-quarter-2025-200100532</guid>
<pubDate>Wed, 06 Aug 2025 20:01:00 GMT</pubDate>
<description>PASADENA, Calif., August 06, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025 and provided recent business and clinical program updates.</description>
</item>
<item>
<title>Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-appoints-raymond-deshaies-phd-board-directors-2025-07-31</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-appoints-raymond-deshaies-phd-board-directors-2025-07-31</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-reports-first-quarter-2025-financial-results-2025-05-07</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-reports-first-quarter-2025-financial-results-2025-05-07</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>-- Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in</description>
</item>
<item>
<title>Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-announces-positive-interim-results-first-human-healthy-volunteer-study-xmab942</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-announces-positive-interim-results-first-human-healthy-volunteer-study-xmab942</guid>
<pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
<description>-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of</description>
</item>
<item>
<title>Xencor Appoints Todd Simpson to Board of Directors</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-appoints-todd-simpson-board-directors-2025-03-17</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-appoints-todd-simpson-board-directors-2025-03-17</guid>
<pubDate>Thu, 13 Mar 2025 04:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-reports-fourth-quarter-and-full-year-2024-financial-results-2025-02-27</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-reports-fourth-quarter-and-full-year-2024-financial-results-2025-02-27</guid>
<pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Reports Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-reports-third-quarter-2024-financial-results-2024-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-reports-third-quarter-2024-financial-results-2024-11-06</guid>
<pubDate>Wed, 06 Nov 2024 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment</description>
</item>
<item>
<title>Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-doses-first-subject-phase-1-2-study-xmabr942-development-patients-inflammatory</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-doses-first-subject-phase-1-2-study-xmabr942-development-patients-inflammatory</guid>
<pubDate>Mon, 04 Nov 2024 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the</description>
</item>
<item>
<title>Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-presents-preclinical-data-xmab942-high-potency-extended-half-life-anti-tl1a</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-presents-preclinical-data-xmab942-high-potency-extended-half-life-anti-tl1a</guid>
<pubDate>Thu, 10 Oct 2024 04:00:00 GMT</pubDate>
<description>-- XmAb942 on track for first subject dosing in Phase 1 healthy volunteer study in Q4 2024 -- PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:</description>
</item>
<item>
<title>Xencor Announces Upcoming Change to Board of Directors</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-announces-upcoming-change-board-directors-2024-10-04</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-announces-upcoming-change-board-directors-2024-10-04</guid>
<pubDate>Fri, 04 Oct 2024 04:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the</description>
</item>
<item>
<title>Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/xencor-inc/news/xencor-announces-closing-public-offering-including-full-exercise-underwriters-option</link>
<guid isPermaLink="true">https://6ix.com/company/xencor-inc/news/xencor-announces-closing-public-offering-including-full-exercise-underwriters-option</guid>
<pubDate>Thu, 12 Sep 2024 04:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for</description>
</item>
</channel>
</rss>